From Microbial Composition to Function

A microbial composition change can be real and still leave the operational question unanswered. Four gates carry the evidence from observation toward decision-grade function: harmonized composition, measured function, controlled human association, and prospective causal testing. Each has its own standard, and careful stewardship does not allow certainty to pass between them.

Human evidence is better at describing microbial composition than at measuring what microbial communities do. The frozen evidence package contains 114 source rows resolving to 72 analysable studies from 2,434 unique records. Twelve T1 actual-flight studies and 17 T3 human-analog studies form the human base. Among 22 retrieved human-tier full texts, 12 report a candidate alpha-diversity statistic and 15 state a direction. Zero reports a functional outcome with a statistic (Gastronaut 2026 synthesis). The record can therefore reveal a shift while leaving the next program team an open question about the action it supports.

For NASA, the four gates form an evidence sequence toward a bounded causal test. For investors, they define technical milestones without assigning a health or commercial premium before the evidence exists. Both decisions depend on preserving what each gate has earned, and no more.

Gate 1: make composition comparable

The first requirement is comparability. Composition data can identify recurring taxa, community shifts, and candidate relationships with exposure. Morrison et al. and Voorhies et al. contribute actual-flight composition evidence at T1. Their service to the record is composition evidence, not an inherited claim about health outcomes.

This gate harmonizes the 12 human-tier records with candidate alpha-diversity statistics. The record preserves the underlying metric, preprocessing method, sampling site, timing, sequencing or assay platform, exposure context, and uncertainty. A common table distinguishes a reported statistic from a narrative direction, and an abstract statement from a full-text result.

Harmonization does not force unlike data into one pooled estimate. It treats comparability and noncomparability with equal care. Gate 1 is met when sample provenance, metric definition, analysis population, timepoint, and reported uncertainty can be reconstructed.

Alpha diversity is not function. A change in richness or evenness does not directly show metabolite production, barrier integrity, immune activity, motility, antimicrobial resistance, or another operationally relevant process. Gate 1 yields a map of composition evidence, not a biological performance conclusion.

Gate 2: measure function directly

The second gate changes the question from microbial presence to measured function. The frozen synthesis contains isolated functional evidence across tiers: one T3 barrier record, one T3 record involving short-chain-fatty-acid producers, T2 animal records involving lymphatic transport and mucosal immunity, and T4 records involving tryptophan metabolism, motility, and antimicrobial resistance or virulence (Gastronaut 2026 synthesis).

These categories remain separate. A taxonomic label associated with a metabolite is not a measured metabolite; a predicted pathway is not an assay result. An animal immune finding does not become a human immune finding. Simulation can nominate a mechanism, but the duty of the evidence record is to stop short of claiming that the same mechanism operates in actual flight.

Where consent, integrity, and available material permit, NASA can use archived samples to test predefined functional markers. Before analysis, the marker, assay, control, detection limit, sample handling, and decision threshold are declared. Gate 2 is met only when function is directly measured and linked to a traceable sample and exposure, so later work inherits both the finding and its conditions.

Gate 3: control the human association

The third gate asks whether a measured function is associated with a human outcome under controlled conditions. Diet and medication can influence both composition and function. Seventeen of 22 retrieved human-tier full texts mention diet, although mention alone does not establish measurement, standardization, or analytical control (Gastronaut 2026 synthesis).

A focused analog study would therefore use a declared diet protocol, medication and supplement record, antimicrobial-exposure history, sampling schedule, and primary functional endpoint. Its plan would cover missing samples, protocol deviations, multiple endpoints, and subgroup analyses. Composition remains a secondary explanatory layer. The primary chain, preserved from one handoff to the next, connects exposure, measured function, and a bounded human outcome.

Even after those controls, human association does not prove causality. A statistically supported relationship can justify a prospective test, but it cannot inherit causal meaning from an animal or simulation study.

Gate 4: test one causal chain prospectively

The final gate tests a declared intervention or storage condition prospectively. In the frozen synthesis, all three microbiome-manipulation studies with host outcomes are T4 simulation designs. No reviewed actual-flight study tests probiotic viability after storage (Gastronaut 2026 synthesis). The corpus therefore stops short of human-tier or actual-flight causal confirmation.

A Gate 4 study selects one causal chain before testing. For example, a storage exposure might link organism identity, viability, a direct functional assay, and a bounded downstream endpoint. The protocol defines controls, acceptance thresholds, redesign triggers, stop conditions, and reporting for unfavorable or null findings.

A controlled ground or analog campaign can resolve assay and storage questions before a higher-tier study is considered. Evidence from that campaign determines whether the next tier is warranted and what responsibility it inherits from the earlier test.

NASA decision

For NASA, the ladder sequences research requirements across four gates:

1. Harmonize the 12 human-tier records that contain candidate alpha-diversity statistics.
2. Analyze suitable archives for one or more predefined functional markers.
3. Run a diet-and-medication-controlled analog study with a primary functional endpoint.
4. Conduct a bounded causal or storage experiment only after the assay and association gates are met.

Each gate ends in a continue, redesign, or stop decision. Data dictionaries, provenance requirements, analysis plans, and null-result reporting are set at entry, before results appear. This discipline keeps a research signal from becoming a program assumption and leaves a clear account for those making the next decision.

Investor decision

Investors can stage support against the same evidence sequence. Their decision concerns technical exposure, separate from NASA’s research progression. Gate 1 asks whether data are harmonizable. Gate 2 asks whether the assay is valid and repeatable. Gate 3 asks whether a reproducible human association remains after declared controls. Gate 4 asks whether a prospective intervention or storage condition changes the predefined functional result.

The structure keeps interpretation and capital exposure within the milestone reached. Composition is a research signal, not a surrogate for function. A functional assay is a measurement capability, not a clinical result. Human association informs study selection, not causal certainty. In each case, restraint protects the credibility of the next claim.

ORCA design objective and evidence boundary

Gastronaut is developing ORCA as a 2.0 m diameter standalone modular cultivation enclosure. It is approximately TRL 3 to 4 and remains at the ground stage, with zero flight and lunar cycles. Its proposed 0.1 g to 1.0 g research range and nominal 0.5 g to 0.65 g operation are design objectives, not demonstrated performance. This maturity boundary determines which part of the evidence ladder ORCA can presently address.

At the ground stage, ORCA could serve as a controlled-exposure and sample-provenance platform if its variables are measured and its records pass the same gates. Design objectives include timestamped environmental data, defined sampling points, custody records, and links between configuration, biological material, assay, and disposition. Gastronaut can offer a proposed data dictionary, resource-accounting template, ground-validation plan, readiness assessment, and operating-history structure. These are company materials, not NASA-validated assets.

ORCA has no microbiome-control or clinical claim. Its role in this framework is testability: preserving the conditions needed to interpret a bounded experiment and carry its evidence forward intact.

Limitations

The synthesis combines multiple study designs, sample types, assays, and evidence tiers. Counts show the structure of the reviewed evidence, not a pooled biological effect. The 22 retrieved human-tier full texts may not represent every relevant publication. The frozen figures come from 114 source rows and 72 analysable studies. A later extraction contains 118 source rows and 75 candidate inclusions but remains unreconciled, so the denominators are not combined.

Constructive engagement request

Gastronaut proposes that NASA and independent assay reviewers select one functional chain, then predefine the four gate criteria. Initial work would identify the composition records, archived material, assay controls, human covariates, and prospective thresholds needed to test it. The resulting decision map would serve NASA’s next-test decision while giving investors a bounded view of the technical milestone reached. It would show what is known, what remains unmeasured, and which result is required to continue, redesign, or stop, leaving the next stage a record it can use with confidence and care.

References

Gastronaut. Gut Microbiome and Immune Function: Frozen Evidence Synthesis. Evidence version frozen 21 Aug. 2026. Research synthesis.

Morrison, M. D., et al. “Investigation of Spaceflight Induced Changes to Astronaut Microbiomes.” Frontiers in Microbiology, 2021, https://doi.org/10.3389/fmicb.2021.659179.

Voorhies, A. A., et al. “Study of the Impact of Long-Duration Space Missions at the International Space Station on the Astronaut Microbiome.” Scientific Reports, 2020, https://doi.org/10.1038/s41598-019-46303-8.